Yasuyuki Kaneta

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 4

Top Topics

Metastatic Colorectal Cancer

Protein Protein

Capillary Electrophoresis

High Throughput

Top Venues

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Kohei Takano, Yoichi Munehira, Mana Hatanaka, Ryo Murakami, Yoshihiro Shibata, Takeshi Shida, Kosuke Takeuchi, Sho Takechi, Toshiki Tabata, Takashi Shimada, Shuhei Kishikawa, Yumi Matsui, Osamu Ubukata, Takahiko Seki, Yasuyuki Kaneta
Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma. Molecular cancer therapeutics 22 (3) (2023)
Kohei Takano, Yoichi Munehira, Mana Hatanaka, Ryo Murakami, Yoshihiro Shibata, Takeshi Shida, Kosuke Takeuchi, Sho Takechi, Toshiki Tabata, Takashi Shimada, Shuhei Kishikawa, Yumi Matsui, Osamu Ubukata, Takahiko Seki, Yasuyuki Kaneta
Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma. Molecular cancer therapeutics 22 (3) (2023)
Kohei Takano, Yoichi Munehira, Mana Hatanaka, Ryo Murakami, Yoshihiro Shibata, Takeshi Shida, Kosuke Takeuchi, Sho Takechi, Toshiki Tabata, Takashi Shimada, Shuhei Kishikawa, Yumi Matsui, Osamu Ubukata, Takahiko Seki, Yasuyuki Kaneta
Discovery of a novel ATP-competitive MEK inhibitor DS03090629 that overcomes resistance conferred by BRAF overexpression in BRAF-mutated melanoma. Molecular cancer therapeutics (2023)
Kohei Takano, Yoichi Munehira, Mana Hatanaka, Ryo Murakami, Yoshihiro Shibata, Takeshi Shida, Kosuke Takeuchi, Sho Takechi, Toshiki Tabata, Takashi Shimada, Shuhei Kishikawa, Yumi Matsui, Osamu Ubukata, Takahiko Seki, Yasuyuki Kaneta
Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma. Molecular cancer therapeutics 22 (3) (2023)